Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. ArQule was incorporated in 1993, and completed a public offering in 1996. ArQule is a biotechnology company engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialise broadly effective cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics. It develops cancer therapies based on its innovative and proprietary Activated Checkpoint Therapy (ACT) platform and its traditional strength in small-molecule chemistry.

ArQule also applies its expertise in the design, production and evaluation of chemical compounds in its chemistry services business. ArQule assists its collaborators with their development programmes by, for example, synthesising potential drug candidates, assessing their suitability and selecting the most promising, by means of high-throughput, automated chemistry.